Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience.

Revista da Associacao Medica Brasileira (1992) - 1 Dec 2019

Tatar Bengu, Köse Şükran, Ergun Nadide Colak, Turken Melda, Onlen Yusuf, Yılmaz Yusuf, Akhan Sıla

Abstract excerpt

OBJECTIVE: The recent development of direct-acting antiviral agents (DAAs) has dramatically changed the treatment of chronic hepatitis C, and interferon-based regimes have become a poor treatment choice in clinical practice. Today DAAs offer shorter, well-tolerated, highly effective curative therapies. This study aimed to evaluate the effectiveness and safety of DAAs in patients with end-stage renal disease and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 2-Naphthylamine
Share to Anilides

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclopropanes

Share to Lactams, Macrocyclic

Share to Macrocyclic Compounds

Share to Ritonavir

Share to Sustained Virologic Response

Share to Uracil

Source

Identifiers

PMID: 31994628
DOI: 10.1590/1806-9282.65.12.1470

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience.PMID 31994628Read ↗

The Efficacy of the Direct-Acting Antiviral Combination in Hemodialysis Patients With Chronic Hepatitis C Virus Genotype 1 InfectionSemantic proximity Read ↗

Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C.Semantic proximity Read ↗

Safety and effectiveness of direct-acting antivirals in patients with chronic hepatitis C and chronic kidney disease.Semantic proximity Read ↗

Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan.Semantic proximity Read ↗

Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis.Semantic proximity Read ↗

Therapy of hepatitis C by direct-acting anti-virals: the end of HCV in dialysis population?Semantic proximity Read ↗

Direct-acting antiviral agents in patients with hepatitis C genotype 1-4 infections in a tertiary hospital.Semantic proximity Read ↗

Direct-acting antiviral regimens in Egyptian patients with chronic hepatitis C virus infection: A real-world single-center experience.Semantic proximity Read ↗

Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience.Semantic proximity Read ↗

Safety and Efficacy of Direct-acting Antiviral Therapies for Chronic HCV Infection in Hemodialysis Patients.Semantic proximity Read ↗

Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.Semantic proximity Read ↗

HEPATITIS C TREATMENT OF RENAL TRANSPLANT AND CHRONIC KIDNEY DISEASE PATIENTS: EFFICACY AND SAFETY OF DIRECT-ACTING ANTIVIRAL REGIMENS CONTAINING SOFOSBUVIR.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.